3) Kindler HL, Friberg G, et al: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23(31): 8033-40, 2005

BIBLIOGRAFIA

1) Hurwitz H, Fehrenbacher L MD Novotny W et al: Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 350: 2335-42, 2004

2) Shah MA, Ramanathan RK et al: Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric cancer or gastroesophageal junction adenocarcinoma. J Clin Oncol 24(33): 5201-6,2006

3) Kindler HL, Friberg G, et al: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23(31): 8033-40, 2005

4) Saltz LB, Rosen LS et al: Phase II trials of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25(30): 4793-99, 2007

5) Tournigand C, André T, Achille E et al: FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J Clin Oncol 15: 229-237, 2004

6) Cunningham D, Humblet Y et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-45, 2004

7) Masi G, Marcucci L et al: First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol. 2006Aug; 17(8): 1249-54, 2006

8)Jonker D, Crhis MD et al: Cetuximab for treatment of colorectal cancer. N Engl J Med 357:2040-8, 2007

9) Van Cutsem E, Moiseyenko VM et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol.24(31): 4991-7, 2006

10) Ajani JA, Fodor MB et al: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 23(24): 5660-7, 2005

11) Lenz HJ, Lee FC et al: Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer.

Epuba head of print, 2006

12) Hildango M, Castellano D et al: Phase I-II study of gemcitabine and fluorouracil as a

continuous infusion in patients with pancreatic cancer. J Clin Oncol 17(2):585-92, 1999

13) Herrmann R, Bodoky G et al: Gemcitabine plus capecitabine compares with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 25(16): 2212-17, 2007

14) Tsavaris N, Kosmas C et al: Second line treatment with oxaliplatin, leucovorin an 5- fluorouracil in gemcitabine-pretreated advanced pancreatic cancer. Invest New Drug: 23(4):

369-75, 2005

15) Zhu AX, Blaszowsky LS et al: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(12): 1898-903, 2006

16) Park SH, Park YH et al: Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 106(2): 361-5, 2006

17) Kerbel RS, Viloria-Petit A, Klement G et al: ‘Accidental’ anti-angiogenic drugs.

Antioncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer, 36: 1248-125, 2000

18) Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest, 105: R15-R24, 2000

19) Man S, Bocci G, Francia G, et al: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res ,62:

2731-2735, 2002

20) Browder T, Butterfield CE, Kraling BM et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug resistant cancer. Cancer Res 60:

1878-1886, 2000

21) Bocci G, Nicolaou KC, Kerbel RS et al: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943, 2002

22) Bocci G, Danesi R, Del Tacca et al: Selective anti-endothelial effects of protracted lowdose BAL-9504, a novel geranylgeranyl-transferase inhibitor. Eur J Pharmacol 477: 17- 21, 2003

23) Bocci G, Francia G, Man S et al: Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003

24) Yesner LM, Huh HY, Pearce SF et al: Regulation of monocyte CD36 and

thrombospondin-1 expression by soluble mediators. Arterioscler Thromb Vasc Biol 16:1019-25, 1996

25) Bocci G, Danesi R, Di Paolo A, Innocenti F, Allegrini G et al: Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-

dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 6:

3032-3037, 2000

26) Neufeld G, Kessler O, Vadasz et al: The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors. Surg Oncol Clin N Am 200: 183-94, 2003

27) Zhu Z, Bohlen P, Witte L et al: Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2: 135-56, 2002

28) Klement G, Huang P et al: Differences in therapeutic indexes of combination metronomic chemotherapy and anti-VEGF-2 antibody in multidrug-resistant human brest cancer xenografts. Clin Cancer Res 8: 221-232. 2002

29) Colleoni M, Orlando L et al: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 17(2):232-8, 2006

30) Glode LM, Barqawi A, Crighton F et al: Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer. Cancer 2003, 98: 1643-8

31) Steinbild S, Arends J et al: Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patient- results of a phase II study. Onkologie 30(12): 629-35, 2997

32) Garcia AA, Hirte H et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer. J Clin Oncol 26: 76-82, 2008

33) F. Loupakis, G. Bocci et al: Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical and

pharmacodynamic evaluation. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part

I. Vol 24, No. 18S (June 20 Supplement), 2006: 13111

34) Fontana A., Bocci G et al: Low-dose metronomic Cyclophosphamide plus Celecoxib and Dexamethasone in Advanced Hormone Refractory Prostate Cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination. Abstract N 1645 ESMO 2006

35) Young SD, Whissel M, Noble et al: Phase II clinical trial results involving treatment with low-dose dayli oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 12(10) 3092-98. 2006

36) Gately S, Kerbel R: Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37: 179-92. 2003

37) Leahy K, Ornberg R, et al: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Canc Res 62:

625-631, 2002.

38) Wu YL, Fu SL et al: Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed Pharmacother 59: 289-92, 2005

39) Silverstein FE, Frich G et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the class study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284 (10):

1247-55, 2000

40) Bresalier RS, Sandler RS et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma ch4moprevention trial. N Engl J Med 352 (11): 1092-102, 2005

41) Solomon DH et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med :162:1099-104, 2002

42) Watson DJ et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med: 162: 1111-15, 2002

43) WitterJ.MedicalOfficerReview.In:http://www.fda.gov/ohrms/dockets/ac/01/

briefing/3677b1_03_med.pdf Accessibilità accertata in giugno 2002.

44) Gislason GH, Jacobsen S et al: Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 113(25):2906-13, 2006

45) Fontana A., Bocci G et al: Low-dose metronomic Cyclophosphamide plus Celecoxib

and Dexamethasone in Advanced Hormone Refractory Prostate Cancer (HRPC): a phase II

clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination. Abstract N 1645 ESMO 2006

46) Young SD, Whissel M, Noble et al: Phase II clinical trial results involving treatment with low-dose dayli oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 12(10) 3092-98. 2006

47) Ravand A, Borner M et al: UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An ECGS for EORTC phase II trial. Eur J Cancer 37(13):

1642-7, 2001

48) Chen JS, Yang TS et al: A phase II trial of uracil-tegafur (UFT) plus leucovorin in the traeatment of advanced biliary tract carcinoma. J Clin Oncol 35(8): 439-43,2005

49) Bennouna J, Perrier H et al: A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 94(1): 69-73, 2006

50) Douillard JY, Hoff PM et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605-16, 2002

51) Carmichael J, Popiela T, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parentelar fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-27, 2002

52) T. Kinoshita, T. Nakajima et al: Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer : results of a randomized trial by national surgical adjuvant study of gastric cancer. J Clinl Oncoly, 2005 ASCO Annual Meeting Proceedings.

Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4021

53) Basaki Y, Chikasa L et al: Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.

Angiogenesis 4(3): 163-73, 2001

54) Basaki Y, Aoyagi K: UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.Oncology :14(9):68-71, 2000

55) Yonekura et al: UFT and its metabolites inhibit the angiogenesis induced by murine

renal cell carcinoma, as determined by a dorsal air sac assay in mice.Clin Cancer Res. 1999

Aug;5(8):2185-91.

56) Munoz R, Man S et al: Highly efficacious non-toxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT cyclophosphamide metronomic chemotherapy. Cancer Res 66(7): 3386-91, 2006

57) Bocci G et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res. 2000; 6: 3032-7

58) Maranuka T, et al. High-pressure liquid chromatographic determination of tegafur [lsqb]1- (tetrahydro-2-furanyl)-5-fluorouracil[rsqb] and uracil in biological materials after oral administration of uracil plus tegafur. J. Pharm. Sci., 59: 1296-1300, 1980

59) Chen HX, Mooney M, et al: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in paztients with advantaced refractory colorectal cancer. J Clin Oncol 24(21): 3354-3360, 2006

60) Ebos JM, Lee CR et al: Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelia growth factor receptor-2 as a surrogate biomarker for tumor growth. Cancer Res. 68(2): 521-9, 2008

61) Lam T, Hetherington JW et al: Metronomic chemoterapy dosing-schedules with estramustine and temozolomide act synergistically with ancti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. Acta Oncol 46(8): 1169-77, 2007

62) Porta C et al: Sorafenib in advantage renal cell carcinoma: serviva and biomarker results from a phase III trial. Presented at the European Association of Urology- 23

Annual EAU Congress, March 26-29, 2008

63) Emi Y, Sumiyoshi Y et al: Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and

gamma-butyrolactone (GBL), the anti-angiogenic metabolities of oral fluoropyrimidine

UFT, in patients with gastric cancer. Fukuoka Igaku Zasshi 98(12): 418-24, 1998